A5064534896- Pituitary Gland Disorders and Treatments
- Adrenal and Paraganglionic Tumors
- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Growth Hormone and Insulin-like Growth Factors
- Ovarian cancer diagnosis and treatment
- Vasculitis and related conditions
- Cerebrospinal fluid and hydrocephalus
- Pharmacological Effects and Toxicity Studies
- Neurological diseases and metabolism
- Mathematical Biology Tumor Growth
- TGF-β signaling in diseases
- Neurological and metabolic disorders
- IgG4-Related and Inflammatory Diseases
- Hedgehog Signaling Pathway Studies
- Parathyroid Disorders and Treatments
- Cancer, Hypoxia, and Metabolism
- Healthcare Systems and Technology
- Thyroid Disorders and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Adrenal Hormones and Disorders
- Hematological disorders and diagnostics
- Thyroid Cancer Diagnosis and Treatment
- Sexual Differentiation and Disorders
Hospital de Santa Maria
2023-2025
Administração Regional de Saúde de Lisboa e Vale do Tejo
2024
Centro Hospitalar Lisboa Norte
2023
University of Lisbon
2023
The crosstalk between tumour cells and microenvironment components in pituitary neuroendocrine tumours (PitNETs), including chemokines, may impact behaviour clinical outcomes. CCL2 was previously identified as a key chemokine PitNETs, but its role remains unknown. We aimed to study the of defining phenotype outcomes regulating macrophage chemotaxis, epithelial-to-mesenchymal transition (EMT) angiogenesis. studied E-cadherin expression, macrophages (CD68 CD163) vessels (CD31) samples from 86...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Introduction According to the 2014 Endocrine Society Clinical Practice Guideline on acromegaly, confirmation of acromegaly diagnosis is established by finding a lack suppression growth hormone (GH) < 1 ug/L following documented hyperglycemia during an oral glucose tolerance test. However, in this setting, concept has never been clearly defined. Objective This study aimed define hyperglycemic threshold required induce GH suppression. Methods We retrieved glycemia profile 44 individuals after...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)